As of fiscal year 2013 Yale research has had 1,815 awards totaling $510.4 million, 416 U.S. and 704 worldwide active patents for Yale inventions, and 58 Yale-founded biotech companies.
The School of Medicine has extraordinary strength in the basic sciences and consistently ranks in the top handful of medical schools receiving funding from the National Institutes of Health.
Toby C. Chai, MD
Darryl T. Martin, Ph.D.Postdoctoral Associate
Dr. Brian Shuch
Brian M. Shuch, MD is a graduate of the University of Michigan and received his MD from New York University before completing his urology residency and surgery internship at the University of California - Los Angeles (UCLA). During residency he completed an NIH/K30 fellowship program in Translational Investigation. He later completed a urologic three-year urologic oncology fellowship at the National Cancer Institute (NCI). He has had several years of kidney and prostate cancer laboratory research experience in the laboratories of Drs. Arie Belldegrun, Marston Linehan, Don Bottaro, Iman Osman, and Samir Taneja. Additionally he has received extensive clinical trial experience from his time at UCLA and the NCI.
Dr. Shuch's research interests involve both translational research and clinical trials. His research focus is the identification of genetic causes of kidney cancer, integrating genomic tools into the patient management, understanding the mechanisms of sarcomatoid transformation, and the development of new therapeutic strategies for high-risk patients. He is working closely with Drs. Harriet Kluger and Mario Sznol to expand the translational kidney cancer research efforts and the clinical trial portfolio at Yale.Since coming to New Haven, Dr. Shuch has helped established a biospecimen repository for the urologic oncology translational research. Additionally he has partnered with Dr. Allen Bale and Ellen Matloff in the Hereditary Cancer Program to form a multi-disciplinary program for Kidney Cancer Genetic Evaluation. This program provides comprehensive genetic evaluation for individuals with familial kidney cancer, early-disease onset, and bilateral/multifocal kidney cancer. Nationally, he is a member of SWOG, the Society of Urologic Oncology Clinical Trials Consortium- Renal Committee, and is a member of the working group for the Cancer Genome Atlas Chromophobe and Papillary Kidney Cancer groups.
Christopher Loose, Ph.D.
CBIT Executive Director
Dr. Loose serves as Executive Director of CBIT, while holding an appointment as Assistant Professor Adjunct in Urology at Yale University. He is also an Accelerator Executive at the Center for Integration of Medicine and Innovative Technology (CIMIT).
In 2006, Dr. Loose co-founded Semprus BioSciences with Massachusetts Institute of Technology (MIT) Institute Professor Robert Langer and David Lucchino, and served as Chief Technology Officer until the company was acquired by Teleflex Incorporated in 2012 (TFX: $80M). A peer-review of the Semprus Technology was published in Science Translational Medicine and received a Frost and Sullivan Breakthrough Technology Award in 2010. Semprus’ first product, a vascular catheter with a surface modification designed to have reduced thrombus (clot) formation, was FDA-cleared in 2012.
Dr. Loose received the prestigious Hertz Foundation Fellowship and was selected by MIT’s Technology Review as a member of the “TR35,” naming the world's top 35 innovators under the age of 35. He was awarded the inaugural Peter Strauss Entrepreneurial Award from the Hertz Foundation in 2011 and was also named to Boston Business Journal's 40 emerging business leaders under 40.
While earning his PhD. in Chemical Engineering at MIT, Dr. Loose co-authored the Semprus Biosciences business plan which won entrepreneurial competitions at MIT, Harvard University and Oxford University. Prior to his graduate work, Dr. Loose was a chemical engineer at Merck Research Labs after graduating summa cum laude with a B.S.E in Chemical Engineering from Princeton University.
Ying (Jean) Zheng, Ph.D.
CBIT Engineering Director
Jean is the Engineering Director for the newly established Center for Biomedical and Interventional Technology (CBIT) at Yale University where she oversees the integration of engineering and medical disciplines to address challenges in patient care. She received her B.S. in Mechanical Engineering from MIT, and M.S. and Ph.D. from Yale, also in Mechanical Engineering. Her doctoral research focused on haptic feedback for variable attention capture (VAC), from which she developed a posture sensing and feedback chair to study seated posture guidance, and a biofeedback weight bearing shoe for partial weight bearing compliance post lower limb orthopedic surgery.
Prior to graduate school, Jean worked for Boston Scientific as an R&D Mechanical Engineer, developing a new line of implantable pacemakers and defibrillators. She was involved in the entire product development lifecycle from concept design and risk assessment (FMEA) to validation testing to final manufacturing (including operator training). Later, she joined Coloplast as an R&D Engineer where she designed female laparoscopic surgery tools and tested them alongside surgeons in cadaver labs.
Jean’s current interests include medical device development (through CBIT), user interface design, social and medical robotics, and STEM outreach.